Active Ingredient: Ramucirumab
Ramucirumab monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥400 ng/ml and who have been previously treated with sorafenib.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
8 - 8 mg per kg of body weight
From 8 To 8 mg per kg of body weight once every 15 day(s)
The recommended dose of ramucirumab as a single agent is 8 mg/kg every 2 weeks.
Patients with HCC should be selected based on a serum AFP concentration of ≥400 ng/ml with a validated AFP test prior to ramucirumab treatment.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
